Literature DB >> 25824248

Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension.

Steffen Desch1, Thomas Okon2, Diana Heinemann2, Konrad Kulle2, Karoline Röhnert2, Melanie Sonnabend2, Martin Petzold2, Ulrike Müller2, Gerhard Schuler2, Ingo Eitel2, Holger Thiele2, Philipp Lurz2.   

Abstract

UNLABELLED: Few data are available with regard to the effectiveness of renal sympathetic denervation in patients with resistant hypertension yet only mildly elevated blood pressure (BP). Patients with resistant hypertension and slightly elevated BP (day-time systolic pressure, 135-149 and diastolic pressure, 90-94 mm Hg on 24-hour ambulatory measurement) were randomized in a 1:1 ratio to renal sympathetic denervation with the Symplicity Flex Catheter (Medtronic) or an invasive sham procedure. The primary efficacy end point was the change in 24-hour systolic BP at 6 months between groups in the intention to treat population. A total of 71 patients underwent randomization. Baseline day-time systolic BP was 144.4±4.8 mm Hg in patients assigned to denervation and 143.0±4.7 mm Hg in patients randomized to the sham procedure. The mean change in 24-hour systolic BP in the intention to treat cohort at 6 months was -7.0 mm Hg (95% confidence interval, -10.8 to -3.2) for patients undergoing denervation and -3.5 mm Hg (95% confidence interval, -6.7 to -0.2) in the sham group (P=0.15). In the per protocol population, the change in 24-hour systolic BP at 6 months was -8.3 mm Hg (95% confidence interval, -11.7 to -5.0) for patients undergoing denervation and -3.5 mm Hg (95% confidence interval, -6.8 to -0.2) in the sham group (P=0.042). In patients with mild resistant hypertension, renal sympathetic denervation failed to show a significant reduction in the primary end point of 24-hour systolic BP at 6 months between groups in the intention to treat analysis. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01656096.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  blood pressure; blood pressure monitoring, ambulatory; randomized controlled trial

Mesh:

Substances:

Year:  2015        PMID: 25824248     DOI: 10.1161/HYPERTENSIONAHA.115.05283

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  59 in total

Review 1.  The rise, fall, and possible resurrection of renal denervation.

Authors:  Rajiv Gulati; Claire E Raphael; Manuela Negoita; Stuart J Pocock; Bernard J Gersh
Journal:  Nat Rev Cardiol       Date:  2016-02-04       Impact factor: 32.419

Review 2.  Resistant Hypertension and Renal Nerve Denervation.

Authors:  Matthew G Denker; Debbie L Cohen
Journal:  Methodist Debakey Cardiovasc J       Date:  2015 Oct-Dec

Review 3.  Resistant Hypertension: An Update of Experimental and Clinical Findings.

Authors:  Anping Cai; David A Calhoun
Journal:  Hypertension       Date:  2017-05-15       Impact factor: 10.190

Review 4.  Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?

Authors:  Hamish Cg Prosser; Cynthia Gregory; Dagmara Hering; Graham S Hillis; Greg Perry; Johan Rosman; Carl Schultz; Mark Thomas; Gerald F Watts; Markus P Schlaich
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

5.  Renal denervation for resistant hypertension: yes.

Authors:  Enrico Boschetti; Yahya Alrashdi; Giuseppe Schillaci
Journal:  Intern Emerg Med       Date:  2016-03-12       Impact factor: 3.397

Review 6.  Device-based therapies for arterial hypertension.

Authors:  Lucas Lauder; Michel Azizi; Ajay J Kirtane; Michael Böhm; Felix Mahfoud
Journal:  Nat Rev Cardiol       Date:  2020-04-14       Impact factor: 32.419

7.  Effectiveness of Renal Denervation in Resistant Hypertension: A Meta-Analysis of 11 Controlled Studies.

Authors:  Marco Pappaccogli; Michele Covella; Elena Berra; Chiara Fulcheri; Silvia Di Monaco; Elisa Perlo; Jacopo Burrello; Silvia Monticone; Denis Rossato; Franco Rabbia; Franco Veglio
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-05-11

8.  Resting Afferent Renal Nerve Discharge and Renal Inflammation: Elucidating the Role of Afferent and Efferent Renal Nerves in Deoxycorticosterone Acetate Salt Hypertension.

Authors:  Christopher T Banek; Mark M Knuepfer; Jason D Foss; Jessica K Fiege; Ninitha Asirvatham-Jeyaraj; Dusty Van Helden; Yoji Shimizu; John W Osborn
Journal:  Hypertension       Date:  2016-10-03       Impact factor: 10.190

Review 9.  Renal sympathetic denervation in therapy resistant hypertension - pathophysiological aspects and predictors for treatment success.

Authors:  Karl Fengler; Karl Philipp Rommel; Thomas Okon; Gerhard Schuler; Philipp Lurz
Journal:  World J Cardiol       Date:  2016-08-26

Review 10.  Catheter-based Renal Artery Denervation for Resistant Hypertension: Promise Unfulfilled or Unsettled?

Authors:  Matthew G Denker; Debbie L Cohen; Raymond R Townsend
Journal:  Curr Atheroscler Rep       Date:  2015-10       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.